The strong buying from high-conviction investors like RenTech and sovereign wealth fund Norges Bank, combined with Fidelity's aggressive doubling, suggests growing optimism about MRNA's post-pandemic pipeline or valuation reset. Traders should monitor upcoming clinical trial updates or partnerships as potential catalysts.
MRNA drugs
MRNA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $52.82entry
- T+1 · 9mo ago −5.93%α −5.01% · $49.69
- T+5 · 8mo ago +5.51%α +6.72% · $55.73
- T+20 · 8mo ago −8.82%α −0.88% · $48.16
- T+60 · 6mo ago −10.96%α −20.29% · $47.03
How similar events traded
Executive Summary
Three major institutions, Fidelity, Norges Bank, and RenTech, significantly increased or initiated positions in Moderna (MRNA) during 2025-Q4, collectively adding over $605M in net new exposure. This buying was partially offset by a modest trim from BofA, which reduced its stake by $17.7M. The cluster suggests growing institutional confidence in MRNA despite recent underperformance.
Key Financial Metrics
Institutional Positions
Net institutional flow: $865.2M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Fidelity | DOUBLED | +127.9% | $827.1M | $509.2M |
| Norges Bank | NEW | +0% | $79.7M | $79.7M |
| RenTech | NEW | +0% | $16.8M | $16.8M |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| BofA | TRIM | -39.1% | $58.3M | -$17.7M |
Key Facts
- Fidelity doubled down on MRNA, increasing its position by 127.9% (15.74M shares) with a $509.2M value increase.
- Norges Bank and RenTech initiated new positions worth $79.7M and $16.8M, respectively.
- BofA trimmed its stake by 39.1%, reducing holdings by $17.7M.
- Net institutional flow: +$588M after accounting for all buyers and sellers.
Financial Impact
3 institutions accumulated $605.7M in net new positions while 1 reduced holdings by $17.7M, resulting in a net positive flow of $588M.
Risk Factors
- MRNA remains sensitive to vaccine demand and trial outcomes; any negative data could reverse sentiment.
- BofA's partial exit may reflect ongoing skepticism about long-term revenue sustainability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-MRNA-2025-Q4 |
Track record
26 reports on MRNA
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers